Cogent Biosciences (COGT) Earnings Analysis
Cogent Biosciences (COGT) has no confirmed upcoming earnings date. Last quarter (2026-02-17) it missed with EPS -0.55 USD vs -0.51 USD est (-7.8%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -12.84.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does COGT next report earnings?
No confirmed upcoming earnings date is currently scheduled for COGT. This page updates as the calendar is published.
COGT earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-17 | -0.55 USD | -0.51 USD | -7.8% | Miss |
| 2025-11-07 | -0.5 USD | -0.54 USD | +7.4% | Beat |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
COGT valuation and analyst view
| Trailing P/E | -12.84 |
|---|---|
| Trailing EPS | -5.25563 USD |
| Price / book | 4.39 |
| Dividend yield | 0.00% |
| Market cap | 6.63B |
| Analyst consensus | Buy (10 buy / 2 hold / 0 sell) |
| Avg price target | 50 USD |
Related research pages
Frequently asked questions
When is Cogent Biosciences (COGT)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for COGT. This page updates as the calendar is published.
Did COGT beat earnings last quarter?
In its 2026-02-17 report, COGT posted EPS of -0.55 USD versus a -0.51 USD estimate — a miss of 7.8%.
What is COGT's earnings track record?
Over the last 2 reported quarters with consensus data, COGT beat estimates 1 times (50%).
What is COGT's current P/E ratio and EPS?
COGT trades at a trailing P/E of -12.84 on trailing EPS of -5.255629394487792 USD.
What do analysts rate COGT?
Analyst consensus is "Buy" across 12 ratings (0 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 50 USD.